OCT 2·SEC EDGARLow
Toy Andrew sold $1.3M of CLOV
Toy Andrew (Chief Executive Officer) sold 318,806 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.19 ($1.34M total) on 2026-10-01 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Healthcare Plans
$CLOV
CLOVER HEALTH INVESTMENTS, CORP. /DE
AlphAI earnings readSecond quarter 2026 · AUG 5Clover Health Reports Second Quarter 2026 ResultsVerdict: strongRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $CLOVvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 0
- Neutral
- 0
- Bearish
- 1
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $3.0M 9 txs
Reynoso Jamie L.4× · $101K
10b5-1 share of filings89%
Top stories · $CLOVMore →
OCT 1·globenewswire.com
Clover Health’s 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value
Clover Health (CLOV) announced its 2027 Medicare Advantage plans, emphasizing PPO choice, preventive care, and member value. The plans feature low premiums, no referrals, and benefits like routine dental and vision. Clover Assistant, the company's technology, supports physicians in identifying care needs. The plans will be available to 5.2 million Medicare-eligible beneficiaries across 203 counties in five states.
SEP 24·tipranks.com
Clover Health Adds Policy and Clinical Experts to Board
Clover Health Investments (CLOV) added former U.S. Senator Robert G. Torricelli and MedPAC Commissioner Dr. Brian J. Miller to its Board of Directors, expanding it to nine members. Torricelli and Miller bring policy and clinical expertise, respectively, to support CLOV's Medicare Advantage strategy and cost-saving initiatives, according to the company.
CLOV sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CLOV (CLOVER HEALTH INVESTMENTS, CORP. /DE). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent CLOV coverage spans financial news, insider activity and corporate actions.
In the last 30 days, CLOV insiders filed 9 SEC Form 4 transactions — no purchases and 9 sales ($3.0M). The most active reporter was Reynoso Jamie L., CEO, Medicare Advantage, with 4 filings. 89% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving CLOV
The insider sale suggests potential downside pressure on CLOV as the market digests a large insider divestment.
The new plan details may improve member acquisition and retention, supporting revenue growth, but the impact is incremental.
Board expansion may improve governance and Medicare Advantage strategy, potentially supporting share price modestly.
Board expansion may improve governance and policy insight, potentially supporting the company's Medicare Advantage strategy.
The insider sale may exert slight downward pressure on CLOV as market perceives reduced confidence from a former officer.
AlphAI scores every news story that mentions CLOV with an AI model for sentiment and relevance, and aggregates insider trades from CLOVER HEALTH INVESTMENTS, CORP. /DE's SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $CLOV
Score
Toy Andrew sold $1.3M of CLOV
Toy Andrew (Chief Executive Officer) sold 318,806 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.19 ($1.34M total) on 2026-10-01 under a Rule 10b5-1 trading plan.
1 min readClover Health’s 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value
Clover Health (CLOV) announced its 2027 Medicare Advantage plans, emphasizing PPO choice, preventive care, and member value. The plans feature low premiums, no referrals, and benefits like routine dental and vision. Clover Assistant, the company's technology, supports physicians in identifying care needs. The plans will be available to 5.2 million Medicare-eligible beneficiaries across 203 counties in five states.
2 min read
Clover Health Adds Policy and Clinical Experts to Board
Clover Health Investments (CLOV) added former U.S. Senator Robert G. Torricelli and MedPAC Commissioner Dr. Brian J. Miller to its Board of Directors, expanding it to nine members. Torricelli and Miller bring policy and clinical expertise, respectively, to support CLOV's Medicare Advantage strategy and cost-saving initiatives, according to the company.
1 min readCLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Clover Health Welcomes Former U.S. Senator Robert Torricelli and MedPAC Commissioner Dr. Brian J. Miller M.D. to Its Board of Directors WILMINGTON, Del., September 24, 2026 — Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”)
1 min readClover Health former officer plans 141,418-share sale
Clover Health's former officer, Brady Priest, plans to sell 141,418 shares, valued at $631,162.68, according to a regulatory filing. Priest also reported four prior sales totaling 1,205,209 shares between August 7 and September 15, 2026, with proceeds ranging from $305,113.45 to $2,171,597.33.
1 min read
Innovative Industrial, Phillips 66, EOG, Clover, Estée Lauder Insider Shake
Insiders at Innovative Industrial Properties (IIPR), Phillips 66 (PSX), EOG Resources (EOG), Clover Health (CLOV), and Estée Lauder (EL) sold shares. Director Scott Shoemaker sold 611 IIPR shares for $34,435. EVP Brian Mandell sold 23,400 PSX shares for $6.2M. EVP Michael Donaldson sold 7,336 EOG shares for $1.09M. VP Joseph Oldakowski sold 20,000 CLOV shares for $103,200. Director Paul Fribourg sold 103,000 EL shares for $10.05M.
1 min readWai Conrad sold $1.4M of CLOV (indirect holdings)
Wai Conrad (CEO, Counterpart Health) sold 300,000 indirectly-held shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.72 ($1.42M total) on 2026-09-15 under a Rule 10b5-1 trading plan.
1 min read
Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know
Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.
2 min readClover Health (CLOV) VP of Finance and Controller Joseph Oldakow
Clover Health's (CLOV) VP of Finance, Joseph Oldakowski, sold 20,000 shares on September 14, 2026, reducing his holdings to 279,067 shares. This follows a pattern of insider selling, with 29 sales and no purchases in the past year. The stock trades at $5.16, with a market cap of $2.71 billion, and is considered modestly overvalued by GuruFocus's valuation model.
2 min readOLDAKOWSKI JOSEPH FRANK sold $103K of CLOV
OLDAKOWSKI JOSEPH FRANK (VP OF FINANCE AND CONTROLLER) sold 20,000 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $5.16 ($0.10M total) on 2026-09-14.
1 min read